Contact us
Home › Why the UK Remains One of the Best Places in the World to Build a Life Sciences Company

Insights & Resources

•

Why the UK Remains One of the Best Places in the World to Build a Life Sciences Company

Lab technician in blue gloves holds a small sterile sample tube labeled with a blue handwritten tag in a clinical lab.

Filed under

For every life sciences founder, one of the earliest strategic decisions is where to build the business. Access to scientific talent matters, but so do investment, regulation, clinical research, infrastructure and the ability to scale internationally.

The global competition to attract innovative life sciences businesses has never been stronger. Countries across North America, Europe and Asia are investing heavily to create environments where biotechnology, medical technology and health technology companies can thrive.

Against this backdrop, the UK continues to stand out as one of the world’s most attractive places to build a life sciences company.

The UK’s advantage is not simply that it produces outstanding science; many countries do that. Its strength comes from bringing together world leading research institutions, experienced investors, a supportive tax environment, a sophisticated healthcare system and a growing focus on translating discoveries into commercially successful businesses.

For founders, this combination provides something increasingly valuable: an ecosystem that can support a company from early scientific discovery through to global growth.

A Scientific Foundation That Continues to Generate Innovation

The UK’s life sciences strength begins with its research base.

Universities including Oxford, Cambridge, Imperial College London and UCL continue to produce internationally recognised research across areas such as biotechnology, genomics, advanced therapies, artificial intelligence and medical technology. This research excellence has created a strong pipeline of spinouts and innovative companies tackling some of the most challenging problems in healthcare.

The UK’s Golden Triangle, the internationally recognised life sciences cluster centred around Cambridge, Oxford and London, has historically been at the heart of this success. These locations bring together leading universities, research institutes, hospitals, investors and established life sciences companies, creating an environment where scientific discovery, investment and commercialisation naturally intersect.

Supporting this ecosystem are organisations such as the BioIndustry Association, One Nucleus and MedCity, which help connect researchers, entrepreneurs, investors and policymakers. Through networking events, policy engagement, international trade missions and investor introductions, they play an important role in helping innovative companies move from discovery to commercial success.

However, the UK’s life sciences landscape is becoming increasingly distributed. Regional ecosystems in cities such as Manchester, Birmingham, Liverpool, Edinburgh, Glasgow and Cardiff are developing their own strengths, supported by universities, NHS partnerships, specialist facilities and growing investor networks.

This expansion is important because successful innovation should not depend solely on geography. A broader national ecosystem creates more opportunities for founders to access talent, infrastructure and expertise wherever they are based.

Turning Scientific Strength into Commercial Success

The UK has always been recognised for its ability to produce world class research. The challenge has historically been ensuring that more of those discoveries translate into successful companies, manufacturing capability and improved patient outcomes.

Recognising this challenge, government policy has increasingly focused on strengthening the pathway from discovery to commercial success. The Life Sciences Sector Plan is backed by more than ÂŁ2 billion of funding, alongside investment through UK Research and Innovation and the National Institute for Health and Care Research. It sets out an ambition to strengthen the UK’s position as a global life sciences leader by improving the pathway from discovery to adoption, with a focus on commercialisation, manufacturing, regulation, healthcare innovation and access to investment.

This broader approach matters because building a successful life sciences company requires more than a scientific breakthrough. It requires an environment that supports each stage between discovery and market adoption. As clinical development becomes increasingly important in attracting investment, the UK’s ability to connect research, healthcare expertise and commercial support is a significant advantage for innovative businesses.

A Tax Environment Designed to Support Innovation

One of the UK’s most attractive features for early-stage life sciences companies is its investment and tax environment.

Life sciences businesses often face long development timelines, significant research costs and considerable uncertainty before reaching commercial success. Access to patient capital is therefore essential.

The Seed Enterprise Investment Scheme, known as SEIS, has become an important tool for early-stage companies, particularly university spinouts and founder led businesses. By providing tax incentives to qualifying investors, SEIS helps reduce the risk of investing in young companies at the earliest stages of development.

As businesses mature, the Enterprise Investment Scheme, known as EIS, continues to support growth by encouraging investment into innovative companies. This is particularly valuable for life sciences businesses, where significant funding is often required before products reach regulatory approval or commercialisation.

Alongside these investment incentives, the UK’s R&D tax relief regime continues to provide valuable support for companies investing in innovative research and development, helping to offset some of the costs associated with scientific and technological advancement.

In practice, these incentives are not simply tax advantages on paper. They can be a critical factor in helping founders secure the investment needed to progress from an idea or research programme into a scalable company.

A Growing Network of Investors Who Understand Innovation

A successful life sciences ecosystem requires more than funding availability. It requires investors who understand the realities of building science driven companies.

The UK benefits from a mature network of angel investors, venture capital firms, family offices and specialist life sciences investors who understand that innovation rarely follows a predictable timeline.

Developing a medicine, diagnostic technology or advanced therapy involves scientific risk, regulatory challenges and lengthy development cycles. Investors who understand these dynamics can provide more than capital. They provide experience, networks and strategic support.

The combination of SEIS and EIS incentives, university commercialisation programmes and an increasingly experienced investor base has helped create one of Europe’s strongest environments for early-stage life sciences funding.

Capital is only part of the story. Organisations such as the BioIndustry Association, One Nucleus and MedCity play an equally important role by connecting founders with investors, researchers, pharmaceutical companies and policymakers. Through conferences, partnering events, policy engagement and international trade missions, they help innovative businesses build the relationships needed to grow.

This is reinforced by the UK’s ability to attract international investors, strategic partners and global pharmaceutical companies seeking access to high quality innovation. For founders, that means not only greater access to capital but also opportunities to build international relationships as businesses scale.

The NHS: A Unique Advantage for Healthcare Innovation

One of the UK’s greatest competitive advantages is the National Health Service.

For companies developing medicines, diagnostics, medical devices and digital health technologies, access to clinical expertise, patient populations and real-world healthcare environments can be invaluable. Through the NHS, NIHR and a network of research active hospitals and academic institutions, the UK offers this at a scale that few countries can match.

There are challenges, particularly around the speed of adoption and procurement, but ongoing reforms focused on clinical trials, health data and innovation adoption demonstrate a clear recognition of the NHS’s role in supporting the next generation of healthcare companies.

The UK’s strengths also extend beyond healthcare delivery. The combination of the NHS, advanced genomics capabilities, world leading universities and a growing artificial intelligence ecosystem creates opportunities in areas such as drug discovery, diagnostics, precision medicine and digital health. As healthcare becomes increasingly data driven, these capabilities are likely to become even more important sources of competitive advantage.

Regulation as a Competitive Advantage

Regulation is often viewed as a barrier by innovative companies, but increasingly it is becoming an area where the UK can differentiate itself.

A clear and efficient regulatory pathway gives companies confidence when deciding where to invest and develop their technologies.

Strengthening the role of the Medicines and Healthcare products Regulatory Agency, improving coordination with organisations such as NICE, and supporting emerging areas such as artificial intelligence, genomics and advanced therapies will be essential in maintaining the UK’s competitiveness.

Regulatory clarity can make the difference between an innovation remaining in development and successfully reaching patients. Increasingly, the UK is also focused on ensuring that innovative companies can scale and remain within the domestic ecosystem. Investment in advanced manufacturing, specialist facilities and innovation infrastructure is helping create an environment where businesses can discover, develop, commercialise and manufacture new technologies at scale.

Rewarding Entrepreneurial Success

The UK ecosystem also recognises that entrepreneurship involves significant risk.

For founders who successfully build and grow businesses, incentives such as Business Asset Disposal Relief can help ensure that entrepreneurial success is rewarded by reducing the capital gains tax rate on qualifying disposals.

While founders are rightly focused on building value, they also consider the long term outcome of their journey. A supportive environment should encourage both the creation of businesses and the rewards that come from successful exits.

The Opportunity Ahead

The UK has many of the ingredients needed to remain a global leader in life sciences: outstanding research, entrepreneurial talent, experienced investors, healthcare expertise and a policy environment increasingly focused on commercialisation.

The next challenge is ensuring that more of the discoveries made in UK laboratories become successful companies that scale internationally.

The opportunity is not simply to create more scientific breakthroughs. It is to build the infrastructure, investment pathways and partnerships needed to turn those breakthroughs into real world impact.

With world leading universities, internationally recognised research institutions, strong clinical research infrastructure, experienced investors, collaborative industry organisations and a growing commitment to innovation adoption, the UK is well positioned to translate scientific excellence into commercial success. Organisations such as the BioIndustry Association and One Nucleus continue to strengthen the ecosystem by bringing together founders, investors, researchers and policymakers, helping innovative companies access the networks and support they need to grow.For founders considering where to build their next life sciences company, this combination offers something rare: access to science, capital, healthcare expertise and commercial support within a single ecosystem.

No ecosystem is perfect, and competition globally is increasing. But the UK’s combination of scientific excellence, investment incentives and innovation infrastructure continues to make it one of the most attractive places in the world to start, grow and scale a life sciences company.

Scientific discovery may begin in the laboratory, but commercial success depends on the strength of the ecosystem surrounding it. That is where the UK continues to distinguish itself.

Building a life sciences company and have questions about R&D tax relief or funding your innovation? Contact our specialist team can help you understand the available opportunities and navigate the next steps.

Contributors

Asma Aslam, Head of Life Sciences and R&D Tax, Frazier & Deeter UK

Explore related insights

Explore Insights & Resources